Exicure to Present at TIDES 2019 on Preclinical and Clinical Development of AST-008

CHICAGO & CAMBRIDGE, Mass.–(BUSINESS WIRE)–Exicure, Inc. (OTCQB: XCUR), the pioneer in gene regulatory and
immunotherapeutic drugs utilizing spherical nucleic acid (SNA™)
constructs, announced a presentation at TIDES: Oligonucleotide and
Peptide Therapeutics, the world’s largest meeting to accelerate
oligonucleotide and peptide products from early discovery to late-stage
development and commercialization.

The talk, “Preclinical and Clinical Development of AST-008, A Toll-like
Receptor Agonist 9 Spherical Nucleic Acid for Immuno-oncology
Applications,” will be presented by Weston Daniel, Exicure Senior
Director of Program Management, at the conference, May 20-23 at
Manchester Grand Hyatt in San Diego.

Presentation Date/Time: Wednesday, May 22, 12:45 – 4:35 p.m. PT
Room:
Seaport A
Session: Oligonucleotide Discovery, Preclinical
and Clinical